PTPI
vs
S&P 500
PTPI
S&P 500
Over the past 12 months, PTPI has underperformed S&P 500, delivering a return of -100% compared to the S&P 500's +14% growth.
Stocks Performance
PTPI vs S&P 500
Performance Gap
PTPI vs S&P 500
Performance By Year
PTPI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Petros Pharmaceuticals Inc
Glance View
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 24 full-time employees. The company went IPO on 2020-12-02. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The firm also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.